

Neurodevelopmental Comorbidities in Children with Asthma

Demet CAN 

Division of Pediatric Allergy and Immunology, University of Health Sciences, Dr. Behçet Uz Children's Hospital, İzmir, Türkiye

Corresponding Author: Demet Can ✉ ddcan15@hotmail.com

ABSTRACT

Asthma is one of the most prevalent chronic diseases in childhood, contributing substantially to global morbidity. Comorbidities are common and may complicate management, impair asthma control, and increase the disease burden. While allergic, metabolic, and psychological conditions are well recognized, neurodevelopmental disorders (NDDs) have recently emerged as comorbidities of particular concern. To review current evidence on the association between childhood asthma and NDDs, with emphasis on attention deficit-hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). A narrative synthesis of the literature was undertaken, focusing on epidemiological studies, proposed biological mechanisms, and clinical implications of co-occurring asthma and NDDs. Children with asthma show consistently higher prevalence rates of ADHD and ASD compared with the general pediatric population. Reported associations are supported by large-scale epidemiologic studies across diverse populations. Potential mechanisms include shared genetic susceptibility, immune dysregulation, systemic inflammation, and early-life environmental exposures. Neurodevelopmental comorbidities may adversely affect asthma outcomes by reducing treatment adherence, impairing symptom perception, and increasing psychosocial burden. Conversely, recurrent respiratory symptoms and chronic inflammation may contribute to neurodevelopmental vulnerability. The coexistence of asthma and NDDs represents a clinically significant and bidirectional relationship. Recognition of these comorbidities is essential for comprehensive care, as they influence both disease management and long-term outcomes. Multidisciplinary approaches integrating pediatric pulmonology, allergy, and neurodevelopmental care are needed. Further research is warranted to clarify causal pathways and develop targeted interventions that address the dual burden of asthma and NDs in children.

Keywords: Neurodevelopmental disorders, attention deficit hyperactivity disorder, autism spectrum disorder, child, comorbidity

Asthma stands as one of the most prevalent chronic inflammatory diseases of childhood globally, impacting millions of children with varying prevalence across geographical regions and socioeconomic conditions (1). Asthma is often associated with various comorbidities. Among the comorbid conditions most frequently reported in patients with asthma are rhinitis, sinusitis, gastroesophageal reflux disease, obstructive sleep apnea, hormonal disorders, and various psychopathologies; additionally, several other conditions—sometimes lacking a clearly defined mechanistic link to asthma—have also been documented as highly prevalent in this population (2). Understanding comorbidities in children is important because these comorbidities not only impose a significant burden on the

patient and family but can also impair asthma control and lead to asthma persistence (3).

The most common comorbidities of asthma in children are allergic rhinitis, sinusitis, atopic dermatitis, gastroesophageal reflux, food allergy, obesity, obstructive sleep apnea, and psychological disturbances. In recent years, neurodevelopmental disorders (NDDs) have garnered increasing attention among these comorbidities (4,5). Neurodevelopmental disorders are a heterogeneous group of conditions that typically emerge early in life and often persist across the lifespan. Common NDDs diagnoses include autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), intellectual disability,

communication disorders, learning disabilities, and motor disorders (6).

Among these conditions, ADHD and ASD are the most prevalent and best-characterized NDDs in childhood and they account for the majority of the clinical and epidemiological literature on asthma-NDDs comorbidity. Several large-scale studies and meta-analyses have demonstrated that children with asthma have significantly higher odds of ADHD compared with those without asthma, and that asthma and ADHD show a bidirectional association over time. Likewise, population-based data indicate a higher prevalence of asthma among children with ASD than among typically developing controls, supporting a non-random co-occurrence of these two conditions (4,5,7).

This review aims to comprehensively examine the complex relationship between asthma and NDDs, focusing specifically on ADHD and ASD. The clinical significance of this relationship, potential pathophysiological mechanisms, and integrated management strategies will be reviewed.

EVIDENCES OF ASSOCIATION

Numerous studies have identified a significant correlation between childhood asthma and NDDs (Table I).

Large-scale epidemiological research has shown that children with asthma are more likely to be diagnosed with ADHD, ASD, and other NDDs compared to their non-asthmatic peers. A study, based on data from the U.S. National Survey of Children's Health, has shown that children with asthma had a 1.7-fold increased risk of ADHD. These associations remain robust even after controlling for variables such as age, gender, and socioeconomic status, indicating a specific link between asthma and neurodevelopmental outcomes (8).

Studies investigating the link between asthma and NDDs generally found a significant association between asthma and ADHD. Two studies in Germany and Taiwan with over a million participants found associations of OR 2.19 and OR 1.53 respectively (9,10).

Longitudinal studies have provided valuable information about the temporal relationship between asthma and NDDs. For example, maternal asthma was found to increase the risk of developing ADHD symptoms in a cohort of Norwegian children (11).

Systematic reviews and meta-analysis present convincing evidence for a notable link between bronchial asthma and ADHD in children. In a Swedish meta-analysis that screened 2,649 potentially eligible citations, a significant

Table I: Epidemiological Studies on the Association Between Asthma and Neurodevelopmental Disorders

Author	Year	Country	Study design	Sample size	Main Findings
Blackman & Conaway (8)	2013	USA	National survey (NSCH)	91,642	Asthma-ADHD risk OR 1.7 (1.7-2.1)
Kotey et al. (17)	2014	USA	National survey	77,951	ASD-Asthma OR 1.35 (1.18-1.55); adj OR 1.19 (1.03-1.36)
Holmberg et al. (22)	2015	Sweden	Twin + cohort	Large twin dataset	Asthma→ADHD OR 1.53 (1.16-2.02)
Zheng et al. (20)	2016	Multi-country	Meta-analysis	175,406	ASD-asthma ns: OR 1.26 (0.98-1.61)
Chen et al. (10)	2017	Taiwan	Claims database	>1.7M	Asthma-ADHD OR 1.53 (1.44-1.63)
Instanes et al. (11)	2017	Norway	Birth cohort	>2.3M	Maternal asthma → ADHD OR 1.5 (1.4-1.6)
Miyazaki et al. (13)	2017	Multi-country	Meta-analysis	5 studies 59,646 children	Pooled OR 1.80 (1.57-2.07)
Cortese et al. (12)	2018	Sweden + Multi	Meta-analysis + registry	Meta: 3M+; Sweden:1.5M	Pooled OR 1.53 (1.41-1.65)
Xie et al. (18)	2020	USA	National survey	>70,000	ASD-Asthma OR 2.25; (1.48-3.41)
Akmatov et al. (9)	2021	Germany	Insurance claims	ADHD 258k; controls 2.3M	Asthma-ADHD OR 2.19 (2.16-2.22)
Kaas et al. (19)	2021	Multi-country	Meta-analysis	Large pooled	ADHD-asthma OR 1.52 (1.42-1.63); ASD-asthma OR 1.12 (0.93-1.34)
Dai & Jin. (14)	2023	Multi-country	Meta-analysis	10 studies 729,375	OR 1.46 (1.41-1.51)

association between asthma and ADHD was demonstrated (12). A meta-analysis by Miyazaki et al., found a combined odds ratio for ADHD in children with asthma of 1.80, indicating a moderate but consistent association (13).

Another meta-analysis, including 729,375 participants, revealed a statistically significant association between ADHD and an increased likelihood of having bronchial asthma. Potential associated factors linking bronchial asthma and ADHD in children include demographic characteristics, healthcare access, socioeconomic factors, comorbidities, genetic susceptibility, immune dysregulation, chronic conditions, growth and development factors, and parental/environmental influence (14).

In a study using the Conners Parent Rating Scale-48, a 48-question multiple-choice questionnaire completed by mothers to identify symptoms of ADHD in their children, the attention deficit score was found to be significantly higher in the asthma group than in the control group (15).

Like ADHD, ASD represents a prevalent disorder that appears to be on the rise (16). In cross-sectional, population-based studies, parents of children with ASD were more likely to report asthma in their offspring than parents of children without ASD (17). The largest study on ASD-asthma comorbidity, using data from the U.S. National Survey of Children's Health, found that children with ASD (aged 0-17 years) had a two-fold increased risk of asthma (18).

However, the evidence for the relationship between asthma and ASD is not very strong. Indeed, another systematic review with meta-analyses investigating the association between asthma and ADHD or ASD in children shows a significant overlap between asthma and ADHD but not between asthma and ASD in children (19). A comprehensive meta-analysis that included ten studies encompassing 175,406 participants and 8,809 ASD cases found no evidence supporting an association between asthma and ASD (20). In contrast, a study conducted in Sweden that employed several genetically informed designs found evidence of familial co-aggregation between asthma and ASD, suggesting that the modest association between the two disorders may be influenced by shared genetic factors (21).

Childhood asthma, especially severe asthma, is associated with ADHD. Studies have also been conducted examining the relationship between asthma severity and

ADHD. In a twin study to evaluate genetic and environmental risk factors on the asthma-ADHD relationship, asthmatic children had a higher risk of also having ADHD. In this study, the magnitude of the association increased with asthma severity [OR 2.84, (95% CI: 1.86-4.35)] for ≥ 4 asthma attacks in the last 12 months and was not affected by asthma treatment (22).

PATHOPHYSIOLOGY

The relationship between asthma and neurodevelopmental comorbidities is not attributed to a single cause but rather emerges from a complex interplay of numerous biological, environmental, and psychosocial factors within a bio-psycho-social model. Potential mechanisms are explained below.

Neuroinflammation

As one of the most prevalent chronic respiratory inflammatory diseases in children, childhood asthma has been implicated in potential neurodevelopmental impacts: emerging evidence suggests that asthma-related chronic inflammation, hypoxia, and immune dysregulation may disrupt central nervous system development, thereby implying a potential connection to the pathogenesis of NDDs (23).

While asthma is primarily characterized by chronic airway inflammation, this inflammatory response frequently becomes systemic, leading to elevated levels of circulating pro-inflammatory cytokines and chemokines. These inflammatory mediators can cross the blood-brain barrier or increase its permeability, thereby gaining access to the central nervous system (23,24). These molecules can trigger microglial activation and subsequent neuroinflammation. Neuroinflammation can disrupt synaptic plasticity, impair neuronal survival, and inhibit neurogenesis (25,26).

The model that most effectively explains neuronal inflammation is the association between maternal asthma and NDDs. Epidemiological studies have demonstrated that maternal asthma during pregnancy confers an increased risk of NDDs such as ASD and ADHD in the offspring. Maternal systemic inflammation may alter the fetal environment, leading to both short- and long-term consequences on the developing brain (25). Mouse models have shown that offspring of mothers with allergic asthma exhibit behavioral and neuroimmune alterations, which are

thought to occur in response to elevations in inflammatory cytokines associated with maternal allergic asthma (i.e., IL-4, IL-5, IL-6, and IL-17). Consistently, mid-pregnancy elevations of IL-4 and IL-5 have been reported in mothers of children diagnosed with ASD (23, 25).

Crucially, chronic inflammation in early life has been shown to adversely affect the development and function of brain regions vital for cognitive functions, attention, impulse control, and social behavior, such as the prefrontal cortex, hippocampus, basal ganglia, and cerebellum. Inflammatory and developmental disruptions in these regions could contribute to executive dysfunction observed in ADHD and the social-communicative deficits characteristic of ASD (27-29).

Chronic Hypoxia

Recurrent or chronic hypoxia, occurring during severe or poorly controlled asthma exacerbations, can have detrimental effects, especially on the developing brain. The immature brain is considerably more vulnerable to oxygen deprivation than the adult brain (30). Hypoxia disrupts neuronal energy metabolism, triggers neuronal apoptosis, leads to myelination abnormalities, and compromises the integrity of synaptic connections (31). These cellular and structural alterations can result in lasting impairments in cognitive functions (attention, memory, learning ability, processing speed), motor coordination, and emotional regulation, thereby contributing to the emergence or exacerbation of NDDs (32).

Sleep Disturbances

Sleep disturbances are remarkably common in children with asthma due to nocturnal symptoms and potential side effects of asthma medications (33). Chronic sleep deprivation or fragmented sleep is a significant factor adversely impacting cognitive functions (attention, concentration, learning, memory), emotional regulation, and behavior. ADHD symptoms (inattention, hyperactivity, impulsivity) can be significantly worsened by sleep deprivation, and sleep problems are a highly prevalent comorbidity in children with ADHD (34,35). Similarly, sleep disturbances are common in children with ASD, potentially exacerbating social-communicative difficulties and repetitive behaviors (36).

Psychosocial Stress due to Chronic Illness

As a chronic illness, asthma imposes significant psychosocial stress on both the child and their family. Anxieties related to disease management (fear of exacerbations, medication concerns, treatment costs), school absenteeism, difficulties in peer relationships, social restrictions, and parental burden can negatively affect the child's stress levels and mental well-being (37). Chronic or toxic stress can influence the brain's stress response systems, particularly the hypothalamic-pituitary-adrenal (HPA) axis, and neurotransmitter systems (e.g., dopamine, serotonin), thereby interfering with neurodevelopmental processes (38).

Socioeconomic status

Socioeconomic status (SES) influences the risk of both physical diseases, such as asthma, and NDDs, including ADHD. Using Causal Mediation Analysis on French birth cohort data, a causal pathway from SES to ADHD symptoms, in part mediated by asthma, was found. An increase in family income at age 3 by one unit resulted in lower ADHD symptoms at age 5, by -0.37 [95% CI: -0.50, -0.24] SDQ-score-points, with additional -0.04 [95% CI: -0.08, -0.01] points reduction indirectly via asthma at age 3 (39).

Genetic and Epigenetic Factors

Both asthma and many NDDs are known to have genetic predispositions (40,41). Research suggests that shared genetic variants or pathways involved in regulating inflammatory responses, immune functions, and neuronal development could influence susceptibility to both asthma and NDDs. For instance, polymorphisms in major histocompatibility complex (MHC) genes, cytokine gene polymorphisms, and genes associated with neurotransmitter pathways may play a role in the pathogenesis of both conditions. Furthermore, epigenetic mechanisms (DNA methylation, histone modifications), where environmental factors (allergen exposure, diet, maternal stress, foetal distress, birth injury or trauma or small for gestational age) can modify gene expression, may also play a crucial role in this relationship (3, 42,43).

Firstly, evidence for a shared familial risk of ASD or ADHD with asthma has been identified in several family design studies. For example, Sun et al., through Swedish register linkages, demonstrated elevated ADHD risk among relatives of individuals with asthma, with stronger

associations observed in those with closer genetic relatedness (44). A single large-scale genomic analysis demonstrated a significant association between asthma and ADHD, supported by shared genetic architecture and potential causal pathways (42). However, *in vitro* gene expression studies using tissues from patients with asthma and ASD have found gene polymorphisms which are involved in inflammation and immune regulation. These may provide an insight into a genetic predisposition for asthma and ASD (3).

Potential Effects of Medication Use

Ongoing research is investigating the neurodevelopmental effects of certain medications used in asthma treatment. Specifically, long-term and high-dose use of systemic corticosteroids has been associated with neuropsychiatric side effects in children, such as irritability, sleep disturbances, mood swings, and, rarely, psychotic symptoms. However, inhaled corticosteroids generally have much lower systemic side effects, and there is no significant evidence of long-term neurodevelopmental impacts (45,46). Neuropsychiatric side effects associated with montelukast use have long been recognized. In 2020, the U.S. Food and Drug Administration acknowledged these potential harms and issued a boxed warning specifically for montelukast regarding the risk of serious mental health side effects. In a large population-based cohort study conducted in Taiwan, the use of leukotriene receptor antagonists was associated with a 6% increased risk of neuropsychiatric adverse events, an 88% increased risk of psychotic disorders, a 10% increased risk of anxiety disorders, and a 27% increased risk of behavioral and emotional disorders compared with inhaled corticosteroids (46).

CLINICAL CONSEQUENCES OF ASTHMA AND NEURODEVELOPMENTAL DISORDERS ASSOCIATION

Asthma hospitalizations reflect significant morbidity, with contributing factors including inadequate asthma control, exposure to environmental triggers, and adherence to treatment regimens. Children with disorders such as ASD and ADHD may experience additional challenges in managing asthma, given the complex interplay between their behavioral and physical health needs (47). Among adolescents with severe ADHD symptoms, poorer adherence to daily asthma controller therapy has been demonstrated, which in turn has been indirectly associated with

increased asthma-related emergency department visits (48). In children with asthma, comorbid ASD has similarly been linked to suboptimal asthma control and a higher likelihood of hospitalization, largely attributable to behavioral barriers to treatment adherence, communication difficulties, and increased sensitivity to environmental triggers (47,49).

Asthma and Attention-Deficit/Hyperactivity Disorder

Attention deficit-hyperactivity disorders are some of the most common NDDs of childhood, characterized by a triad of inattention, hyperactivity, and impulsivity. Most epidemiological studies consistently demonstrate a two to three times higher prevalence of ADHD in children with asthma compared to the general pediatric population (5,50). This relationship is considered bidirectional: asthma may increase the risk of ADHD, and ADHD, in turn, can negatively impact asthma management (51).

Children with ADHD may struggle with consistent adherence to asthma medications, proper inhaler technique, or compliance with asthma action plans due to inattention and impulsivity (50). This can lead to worsening asthma symptoms and an increased risk of exacerbations.

Asthmatic children with ADHD may experience higher rates of emergency department visits and hospitalizations for asthma exacerbations. Delayed recognition of symptoms, medication non-adherence, or risky behaviors could contribute to this trend (49,52).

The co-occurrence of both chronic conditions can significantly impair the child's academic performance, social relationships, and overall quality of life. These children may face more academic struggles, peer rejection, and behavioral problems at school.

Asthma and ASD

Autism spectrum disorder (ASD) is a complex NDD characterized by repetitive, restricted, and stereotyped behaviors, along with persistent difficulties with social interaction and communication (53). Recent large-scale cohort studies and meta-analyses have provided evidence suggesting an increased risk of ASD in children with asthma and/or a history of allergic diseases (5,54). This association is often explained through the lens of early life immune dysregulation and neuroinflammation mechanisms (5,55).

Sensory processing differences and communication difficulties common in children with ASD can make it challenging for them to perceive, express, or react appropriately to asthma symptoms (e.g., shortness of breath, chest tightness). This could delay the recognition of asthma exacerbations and hinder timely intervention (56).

Children with ASD's intolerance to routine changes or specific sensory sensitivities (e.g., taste/smell of an inhaler, feel of a face mask) can make adherence to asthma medications or regular follow-up appointments challenging. Asthma symptoms or treatment procedures may lead to increased anxiety, meltdowns, or repetitive behaviors in children with ASD (47, 56).

Other Neurodevelopmental and Psychiatric Comorbidities

Anxiety Disorders and Depression

The prevalence of anxiety disorders and depression is higher in children with asthma, particularly those with chronic and poorly controlled asthma, compared to the general population (57,58). This can be attributed to both the inherent stress of living with a chronic illness and the impact of asthma-related inflammatory processes on mood regulation.

Learning Disabilities

Factors such as the burden of chronic illness, frequent school absenteeism, sleep disturbances, and co-occurring ADHD can increase the risk of learning disabilities in children with asthma (59).

Sensory processing disorder

Sensory processing disorder, a neurodevelopmental condition characterized by atypical responses to sensory stimuli, may also be linked to asthma through shared inflammatory mechanisms. In a recent study, asthma was associated with increased risk of atypical sensory processing, particularly in the tactile (OR: 5.716, 95% CI: 2.9-11.) and balance/movement (OR: 8.8, 95% CI: 2.5-30.7) domains (60).

MANAGEMENT STRATEGIES

The presence of neurodevelopmental comorbidities in children with asthma highlights that traditional approaches focusing solely on asthma management may be insuffi-

cient. An integrated and multifaceted clinical approach is essential to optimize the health and development of these children:

Early Diagnosis

Systematic and regular screening for neurodevelopmental problems is critically important for every child diagnosed with asthma, especially those presenting with ongoing behavioral, cognitive, or social-emotional difficulties. Screening tools (e.g., Vanderbilt ADHD Diagnostic Rating Scale, Childhood Autism Rating Scale (CARS), developmental screening inventories) and standardized scales can be utilized. Positive screening results necessitate a detailed diagnostic evaluation by a child psychiatrist, developmental pediatrician, or pediatric neurologist (61).

Multidisciplinary Approach

Multidisciplinary team collaboration is vital when asthma and NDDs co-occur. This team should ideally include a pediatrician, pediatric allergist, child psychiatrist, developmental pediatrician, child neurologist, psychologist, special education specialist, physiotherapist, speech and language therapist, and school nurse among other relevant healthcare and educational professionals. Regular communication and coordination among team members ensure effective management of both conditions and support for all areas of the child's development.

Optimizing Asthma Treatment

One particular challenge for children with concurrent asthma and ADHD and their parents is adequate disease management, such as appropriate use of inhalers, as well as stress and anxiety management to avoid asthma exacerbations. Effective control of asthma symptoms can have a positive impact on neurodevelopmental manifestations by reducing detrimental factors such as chronic inflammation, hypoxia, and sleep disturbances. Prioritizing regular medication adherence (especially inhaled corticosteroids) and compliance with asthma action plans is crucial (3).

Parent Education, Support, and Empowerment

Providing parent education, access to psychosocial support services (counseling, therapy), and referrals to support groups can empower families and strengthen their coping mechanisms. Reducing parental stress and enhancing well-being directly and positively impacts the child's overall health and development.

School and Environmental Accommodations

It is essential to ensure that the child's needs for both asthma and NDs are met within the school environment. School nurses and teachers should be informed about the child's asthma action plan and behavioral support plans for ADHD/ASD. Academic accommodations, special education support, and strategies to foster positive peer relationships should be implemented.

CONCLUSION

While asthma is a significant chronic disease of childhood, its strong comorbidity with NDDs underscores the necessity of a holistic approach to disease management. A multitude of mechanisms, including chronic inflammation, hypoxia, sleep disturbances, psychosocial stress, and genetic predispositions, form the bedrock of this complex relationship. The rising prevalence of ADHD, ASD, and other NDDs in asthmatic children mandates clinicians to possess a high level of awareness regarding these comorbidities, perform systematic screening, and implement integrated treatment plans within a multidisciplinary team framework.

Early diagnosis and timely intervention are critically important to optimize both the respiratory health and the cognitive, behavioral, and social development of children with asthma. This holistic approach will not only target symptom control but also aim to enhance the child's overall well-being, academic success, and quality of life, enabling these children to reach their full potential. Greater awareness and tailored clinical management strategies are crucial for addressing the needs of this at-risk population. Further research is warranted to elucidate the underlying biological and behavioral pathways driving these associations, thereby guiding the development of more effective therapeutic interventions.

Acknowledgement

I would like to thank the artificial intelligence software I used to proofread my article in academic English.

REFERENCES

- Global Initiative for Asthma (GINA). (2024). Global Strategy for Asthma Management and Prevention. Retrieved from <https://ginasthma.org/>
- Boulet LP, Boulay ME. Asthma-related comorbidities. *Expert Rev Respir Med* 2011;5(3):377-93.
- Brew BK, Caffrey Osvald E, Gong T, Hedman AM, Holmberg K, Larsson H, et al. Paediatric asthma and non-allergic comorbidities: A review of current risk and proposed mechanisms. *Clin Exp Allergy* 2022;52(9):1035-47.
- Boulet LP. Influence of comorbid conditions on asthma. *Eur Respir J* 2009;33(4):897-906.
- Guclu YA, Erkoyun E, Celik SS, Can D. The relationship between allergic diseases and neurodevelopmental disorders in children enrolled in primary healthcare. *Pak J Med Sci* 2025;41(2):404-8.
- Qu X, Lee LC, Ladd-Acosta C, Hong X, Ji Y, Kalb LG, et al. Association between atopic diseases and neurodevelopmental disabilities in a longitudinal birth cohort. *Autism Research* 2022;15(4):740-50.
- Zhou H, Chen Z, Zhao W, Liu Y, Cui Y. Evaluation of neuropsychiatric comorbidities and their clinical characteristics in Chinese children with asthma using the MINI kid tool. *BMC Pediatr* 2019;19(1):454.
- Blackman JA, Conaway, MR. Developmental, emotional and behavioral co-morbidities across the chronic health condition spectrum. *J Pediatr Rehabil Med* 2013;6(2):63-71.
- Akmatov MK, Ermakova T, Batzing J. Psychiatric and nonpsychiatric comorbidities among children with ADHD: an exploratory analysis of Nationwide claims data in Germany. *J Atten Disord* 2021;25(6): 874-84.
- Chen M-H, Su T-P, Chen Y-S, Hsu JW, Huang KL, Chang WH, et al. Comorbidity of allergic and autoimmune diseases among patients with ADHD. *J Atten Disord* 2017;21(3):219-27.
- Instanes JT, Halmøy A, Engeland A, Haavik J, Furu K, Klungsoyr K. Attention-deficit/hyperactivity disorder in offspring of mothers with inflammatory and immune system diseases. *Biol Psychiatry* 2017;81(5):452-9.
- Cortese S, Sun S, Zhang J, Sharma E, Chang Z, Kuja-Halkola R, et al. Association between attention deficit hyperactivity disorder and asthma: a systematic review and meta-analysis and a Swedish population-based study. *Lancet Psychiatry* 2018;5(9):717-26.
- Miyazaki C, Koyama M, Ota E, Swa T, Mlunde LB, Amiya RM, et al. Allergic diseases in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis. *BMC Psychiatry* 2017;17(1):120.
- Dai Y, Jin N. Association and Interacting Factors between Bronchial Asthma and Attention-deficit Hyperactivity Disorder in Children: Meta-analysis and Systematic Review. *Actas Esp Psiquiatr* 2023;51(6):262-70.
- Yuksel H, Sogut A, Yilmaz O. Attention deficit and hyperactivity symptoms in children with asthma. *J Asthma* 2008;45:545-7.
- Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden Braun K, et al. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. *Res Dev Disabi* 2012;33(2):467-76.
- Kotey S, Ertel K, Whitcomb B. Co-occurrence of autism and asthma in a nationally-representative sample of children in the United States. *J Autism Dev Disord* 2014;44 (12):3083-8.

18. Xie L, Gelfand A, Delclos GL, Atem FD, Kohl HW 3rd, Messiah SE. Estimated prevalence of asthma in US children with developmental disabilities. *JAMA Netw Open* 2020;3(6):e207728.
19. Kaas TH, Vinding RK, Stokholm J, Bønnelykke K, Bisgaard H, Chawes BL. Association between childhood asthma and attention deficit hyperactivity or autism spectrum disorders: A systematic review with meta-analysis. *Clin Exp Allergy* 2021;51(2):228-52.
20. Zheng Z, Zhang L, Zhu T, Huang J, Qu Y, Mu D. Association between asthma and autism spectrum disorder: A Meta-Analysis. *PLoS ONE* 2016;11(6):e0156662.
21. Gong T, Lundholm C, Lundström S, Kuja-Halkola R, Taylor MJ, Almqvist C. Understanding the relationship between asthma and autism spectrum disorder: a population-based family and twin study. *Psychol Med* 2023;53(7):3096-104.
22. Holmberg K, Lundholm C, Anckarsäter H, Larsson H, Almqvist C. Impact of asthma medication and familial factors on the association between childhood asthma and attention-deficit/hyperactivity disorder: a combined twin- and register-based study: Epidemiology of Allergic Disease. *Clin Exp Allergy* 2015;45(5):964-73.
23. Tamayo JM, Osman HC, Schwartzter JJ, Ashwood P. The influence of asthma on neuroinflammation and neurodevelopment: From epidemiology to basic models. *Brain Behav Immun* 2024;116:218-28.
24. Barnes P J. The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* 2008;118(11):3546-56.
25. Tamayo JM, Osman HC, Schwartzter JJ, Pinkerton KE, Ashwood P. Characterizing the neuroimmune environment of offspring in a novel model of maternal allergic asthma and particulate matter exposure. *J Neuroinflammation* 2023;20(1):252.
26. Ifejeokwu OV, Do AH, El Khatib SM, Ho NN, Zavala A, Othy S, Acharya MM. Immune checkpoint inhibition perturbs neuroimmune homeostasis and impairs cognitive function. *J Exp Clin Cancer Res* 2025;44(1):183.
27. Kern JK, GeierDA, King PG, Sykes LK, Mehta JA, Geier MR. Shared Brain Connectivity Issues, Symptoms, and Comorbidities in Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, and Tourette Syndrome. *Brain Connect* 2015;5(6):321-35.
28. Sies H. Oxidative stress: a concept in redox biology and medicine. *Redox Biol* 2015;4:180-3.
29. Zhuang TT, Pan C, Chen JJ, Han F, Zhu XL, Xu H, Lu YP. Chronic asthma-induced behavioral and hippocampal neuronal morphological changes are concurrent with BDNF, cofilin1 and Cdc42/RhoA alterations in immature mice. *Brain Res Bull* 2018;143:194-206.
30. Kirkham FJ, Datta AK. Hypoxic adaptation during development: relation to pattern of neurological presentation and cognitive disability. *Dev Sci* 2006;9(4):411-27.
31. Guo RB, Sun PL, Zhao AP, Gu J, Ding X, Qi J, et al. Chronic asthma results in cognitive dysfunction in immature mice. *Exp Neurol* 2013;247:209-17.
32. Cortese S, Aoki YY, Itahashi T, Castellanos FX, Eickhoff SB. Systematic Review and Meta-analysis: Resting-State Functional Magnetic Resonance Imaging Studies of Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry* 2021;60(1):61-75.
33. Lal C, Strange C, Bachman D. Neurocognitive impairment in obstructive sleep apnea. *Chest* 2012;141(6):1601-10.
34. Yeo AJ, Cohenuram A, Dunsiger S, Boergers J, Kopel SJ, Koinis-Mitchell D. The Sleep Environment, Napping, and Sleep Outcomes among Urban Children With and Without Asthma. *Behav Sleep Med* 2024;22(1):76-86.
35. Lim J, Dinges DF. Sleep deprivation and vigilant attention. *Ann N Y Acad Sci* 2008; 1129:305-22.
36. Mazurek MO, Sohl K. Sleep and Behavioral Problems in Children with Autism Spectrum Disorder. *J Autism Dev Disord* 2016;46(6):1906-15.
37. Shonkoff JP, Garner AS. Committee on Psychosocial Aspects of Child and Family Health; Committee on Early Childhood, Adoption, and Dependent Care; Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics* 2012;129(1): e232-46.
38. Gunnar M, Quevedo K. The neurobiology of stress and development. *Annu Rev Psychol* 2007;58:145-73.
39. Omura M, Cortese S, Bailhache M, Navarro MC, Melchior M, van der Waerden J, et al. Associations between symptoms of attention-deficit hyperactivity disorder, socioeconomic status and asthma in children. *Npj Ment Health Res* 2024;3(1):22.
40. Haider S, Simpson A, Custovic A. Genetics of Asthma and Allergic Diseases. *Handb Exp Pharmacol* 2022;268:313-329.
41. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* 2019;51(3):431-44.
42. Zhu Z, Zhu X, Liu CL, Shi H, Shen S, Yang Y, et al. Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis. *Eur Respir J* 2019;54(6):1901507.
43. Juan M Tamayo JM, Rose D, Church JS, Schwartzter JJ, Ashwood P. Maternal Allergic Asthma Induces Prenatal Neuroinflammation. *Brain Sci* 2022;12(8):1041.
44. Sun S, Kuja-Halkola R, Chang Z, Cortese S, Almqvist C, Larsson H. Familial liability to asthma and ADHD: A Swedish national register-based study. *JCPP Adv* 2021;1: e12044.
45. Savas M, Vinkers CH, Rosmalen JGM, Hartman CA, Wester VL, van den Akker ELT, et al. Systemic and Local Corticosteroid Use Is Associated with Reduced Executive Cognition, and Mood and Anxiety Disorders. *Neuroendocrinology* 2020;110(3-4):282-91.
46. Yao TC, Huang JL, Wu CS, Horng-Shing Lu H, Chang YC, et al. Comparative Risk of Neuropsychiatric Adverse Events Associated With Leukotriene-Receptor Antagonists Versus Inhaled Corticosteroids. *J Allergy Clin Immunol Pract* 2025;13(4): 903-11.e5.
47. Lin DX, Chang YT, Lo YC, Weng SM. Impact of ASD and ADHD on pediatric asthma exacerbations: a retrospective analysis of the Nationwide Inpatient Sample 2005-2020. *Ital J Pediatr* 2025;51(1):135.

48. Milne Wenderlich A, Montes G, Frey S. Comorbid ADHD and asthma in adolescents; unique challenges and opportunities for care. *J Adolesc Health* 2023;73(5):797-8.
49. Silverstein GD, Arcoleo K, Rastogi D, Serebrisky D, Warman K, Feldman JM. The relationship between pediatric Attention-Deficit/Hyperactivity disorder symptoms and asthma management. *J Adolesc Health* 2023;73(5):813-9.
50. Tsai CJ, Chou PH, Cheng C, Lin CH, Lan TH, Lin CC. Asthma in patients with attention-deficit/hyperactivity disorder: a nationwide population-based study. *Ann Clin Psychiatry* 2014;26(4):254-60.
51. Jiang Z, Long X, Die X, Hou J, Wang Y, Wang Y, Feng W. Causal effects of pediatric asthma on psychiatric disorders: a bidirectional Mendelian randomization study. *J Asthma* 2025;62(3):445-55.
52. Borschuk AP, Rodweller C, Salorio CF. The influence of comorbid asthma on the severity of symptoms in children with attention-deficit hyperactivity disorder. *J Asthma* 2018;55(1):66-72.
53. Tabolacci C, Caruso A, Micai M, Galati G, Lintas C, Pisanu ME, Scattoni ML. Biogenic Amine Metabolism and Its Genetic Variations in Autism Spectrum Disorder: A Comprehensive Overview. *Biomolecules*. 2025;15(4):539.
54. Saad K, Ezzat M, Elhoufey A, Ahmed ME, Al-Atram AA, Fageeh MM, Hamed Y. Asthma and Atopic Diseases in Children with Autism Spectrum Disorders. *J Pharm Bioallied Sci*. 2024;16(Suppl 4):S3209-S311.
55. Lyall K, Van de Water J, Ashwood P, Hertz-Picciotto I. Asthma and Allergies in Children With Autism Spectrum Disorders: Results From the CHARGE Study. *Autism Res* 2015;8(5):567-74.
56. Lu S, Sonney J, Kieckhefer GM. Asthma management in children with autism spectrum disorders: pearls for a successful clinical encounter. *J Pediatr Health Care* 2014;28(6):559-64.
57. Lu Y, Mak K-K, van Bever HPS, Ng TP, Mak A, Ho RC-M. Prevalence of anxiety and depressive symptoms in adolescents with asthma: a meta-analysis and meta-regression. *Pediatr Allergy Immunol* 2012;23(8): 707-15.
58. Averill SH, McQuillan ME, Slaven JE, Weist AD, Kloepfer KM, Krupp NL. Assessment and management of anxiety and depression in a pediatric high-risk asthma clinic. *Pediatr Pulmonol* 2024;59(1):137-45.
59. Koinis-Mitchell D, Kopel SJ, Farrow ML, McQuaid EL, Nassau JH. Asthma and academic performance in urban children. *Ann Allergy Asthma Immunol* 2019;122(5):471-7.
60. Uzunoğlu B, Fırat E, Karadeniz İ, Çelik FÇ, Karkınar CŞÜ, Sancaklı Ö, Can D. Sensory Processing Disorder Could Be a Comorbidity of Childhood Asthma: A Cross-Sectional Study. *Pediatr Pulmonol* 2025;60(7):e71203.
61. Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatrics* 2019;144(4):e20192528.